Document is current
Any future updates will be listed below
-
Authors
Fisher, Katie https://orcid.org/0000-0002-8732-706X
Garcia, Mauro A.
Frattari, Giacomo S. https://orcid.org/0000-0001-7765-6428
Naasz, Chloé
Zhuo, Junlin https://orcid.org/0000-0002-5311-6707
Rosás-Umbert, Miriam https://orcid.org/0000-0002-2850-6586
Dietz, Lisa L. https://orcid.org/0000-0002-1797-5766
Juhl, Anna Karina
Falling Iversen, Emma https://orcid.org/0000-0003-2770-1942
Olesen, Rikke
Schleimann, Mariane H.
Pahus, Marie H.
Johansen, Isik S.
Henderson, Merle
Carrere, Leah
Roseto, Isabelle https://orcid.org/0009-0008-2976-0720
Gao, Ce https://orcid.org/0000-0002-3775-790X
Yu, Xu G.
Fray, Emily J. https://orcid.org/0000-0002-5850-6237
Aydin, Beril https://orcid.org/0009-0004-4416-8726
Lubbeck, Donald https://orcid.org/0009-0004-6093-0602
Lai, Jun
Simonetti, Francesco R. https://orcid.org/0000-0002-4165-660X
Danesh, Ali
Miller, Itzayana https://orcid.org/0000-0001-9199-8985
Mendoza, Pilar
Niessl, Julia https://orcid.org/0000-0001-8852-1924
Gaebler, Christian https://orcid.org/0000-0001-7295-8128
Seaman, Michael S.
Kaufmann, Daniel E.
Lehmann, Clara
Gruell, Henning https://orcid.org/0000-0002-0725-7138
Klein, Florian https://orcid.org/0000-0003-1376-1792
Caskey, Marina https://orcid.org/0000-0003-1727-8693
Nussenzweig, Michel C. https://orcid.org/0000-0003-0592-8564
Tolstrup, Martin https://orcid.org/0000-0001-7020-5173
Jones, R. Brad https://orcid.org/0000-0003-4470-1231
Gunst, Jesper D. https://orcid.org/0000-0002-3787-0259
Siliciano, Janet D. https://orcid.org/0000-0001-6712-3775
Lichterfeld, Mathias https://orcid.org/0000-0001-9865-8350
Siliciano, Robert F. https://orcid.org/0000-0002-1764-1993
Søgaard, Ole S. https://orcid.org/0000-0001-9107-2023
- License Information
-
More Information
Article History
Received: 4 June 2025
Accepted: 30 January 2026
First Online: 3 March 2026
Competing interests
: O.S.S. declares serving on scientific advisory boards for Abbvie, ViiV Healthcare, Gilead Sciences, Immunocore and Merck. Aspects of the IPDA are the subject of patent application PCT/US16/28822 filed by J.H.U. with R.F.S. as an inventor and licensed to AccelevirDx. F.R.S. received payments from Gilead for participating at scientific meetings. R.B.J. has served as an advisor to ViiV Healthcare and received payment for this role. M.L. has acted as a paid consultant for ViiV, Merck and MPM BioImpact. H.G. and F.K. are inventors on patent applications on HIV-neutralizing antibodies filed by the University of Cologne and have received compensation from the University of Cologne for licensed patents. P.M. is currently employed by Pfizer Vaccines, which researches and develops antiviral therapeutics and vaccines for profit. J.N. is currently employed by BioNTech SE. C.L. received payments from Gilead for participating at scientific meetings and declares serving on scientific advisory boards for Pfizer, ViiV Healthcare, Gilead Sciences and Merck. M.C. served on scientific advisory boards for Gilead, Merck and ViiV. M.C.N. is an inventor on antibody patents licensed by the Rockefeller University to Gilead. C. Gaebler received travel support from Gilead Sciences for participating at scientific meetings. The remaining authors declare no competing interests.
